Biocon Biologics Ltd. has received FDA approval for KIRSTY™ (Insulin Aspart-xjhz) as the first interchangeable biosimilar to NovoLog®, expanding treatment choices for diabetes patients in the U.S. KIRSTY™ is available in prefilled pens and vials for subcutaneous and intravenous use. With 38.4 million Americans having diabetes, the approval addresses a significant need. Biocon Biologics is a global leader in biosimilars, serving over 5.8M patients annually. KIRSTY™’s approval is based on data showing its similarity to NOVOLOG with no clinically meaningful differences. Safety information and precautions for KIRSTY™ have also been detailed.

Additionally, Biocon Biologics has commercialized nine biosimilars worldwide and has a pipeline of 20 biosimilar assets across various therapeutic areas. The company is focused on transforming healthcare by providing affordable access to high-quality biosimilars. The FDA approval of KIRSTY™ marks a significant milestone in making insulin more accessible and affordable for patients with diabetes. With a commitment to scientific excellence and patient-centric innovation, Biocon Biologics aims to address unmet needs in diabetes care.

Read more at GlobeNewswire: Biocon Biologics Expands Diabetes Portfolio with FDA